Kalender
| Tid* | ||
| 2026-03-05 | 06:00 | Bokslutskommuniké 2025 |
| 2025-11-26 | 06:00 | Kvartalsrapport 2025-Q3 |
| 2025-09-17 | 06:00 | Kvartalsrapport 2025-Q2 |
| 2025-06-25 | N/A | Årsstämma |
| 2025-06-10 | 06:00 | Kvartalsrapport 2025-Q1 |
| 2025-03-05 | 06:00 | Bokslutskommuniké 2024 |
| 2024-12-20 | - | Extra Bolagsstämma 2024 |
| 2024-11-27 | - | Kvartalsrapport 2024-Q3 |
| 2024-09-12 | - | Kvartalsrapport 2024-Q2 |
| 2024-06-28 | - | Kvartalsrapport 2024-Q1 |
| 2024-06-27 | - | X-dag ordinarie utdelning SOFTX 0.00 NOK |
| 2024-06-26 | - | Årsstämma |
| 2024-03-20 | - | Bokslutskommuniké 2023 |
| 2023-10-26 | - | Kvartalsrapport 2023-Q3 |
| 2023-09-26 | - | Kvartalsrapport 2023-Q2 |
| 2023-06-21 | - | Årsstämma |
| 2023-06-21 | - | Kvartalsrapport 2023-Q1 |
| 2023-03-30 | - | X-dag ordinarie utdelning SOFTX 0.00 NOK |
| 2023-02-17 | - | Bokslutskommuniké 2022 |
| 2022-12-09 | - | Extra Bolagsstämma 2022 |
| 2022-10-26 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-15 | - | Kvartalsrapport 2022-Q2 |
| 2022-04-28 | - | Kvartalsrapport 2022-Q1 |
| 2022-04-19 | - | X-dag ordinarie utdelning SOFTX 0.00 NOK |
| 2022-04-17 | - | Årsstämma |
| 2022-02-16 | - | Bokslutskommuniké 2021 |
| 2021-12-29 | - | Extra Bolagsstämma 2021 |
| 2021-11-17 | - | Kvartalsrapport 2021-Q3 |
| 2021-09-08 | - | Kvartalsrapport 2021-Q2 |
| 2021-04-29 | - | Kvartalsrapport 2021-Q1 |
| 2021-04-14 | - | X-dag ordinarie utdelning SOFTX 0.00 NOK |
| 2021-04-13 | - | Årsstämma |
| 2021-02-09 | - | Bokslutskommuniké 2020 |
| 2020-12-14 | - | Kvartalsrapport 2020-Q3 |
| 2020-09-30 | - | Kvartalsrapport 2020-Q2 |
| 2020-07-01 | - | X-dag ordinarie utdelning SOFTX 0.00 NOK |
| 2020-06-30 | - | Årsstämma |
| 2020-06-30 | - | Kvartalsrapport 2020-Q1 |
| 2019-12-20 | - | Extra Bolagsstämma 2019 |
| 2019-06-27 | - | Årsstämma |
| 2019-06-03 | - | X-dag ordinarie utdelning SOFTX 0.00 NOK |
| 2018-07-02 | - | Split SOFTX 1:50 |
Beskrivning
| Land | Norge |
|---|---|
| Lista | Euronext Growth Oslo |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
2024-06-02 06:11:08
A peer-reviewed article describing a study investigating the safety and
tolerability as well as wound size effect and antimicrobial efficacy of SOftOx
Biofilm Eradicator has just been accepted by the top ranked medical wound
journal "Advances in Wound Care".
"The conclusion in the study is very interesting. It shows SBE is safe and
tolerable in humans. In addition SBE reduced the bioburden and strongly improved
wound closure", says Thomas Bjarnsholt, professor at Copenhagen University.
A first-in-human clinical study investigating the safety and tolerability of
stabilized hypochlorous acid in patients with chronic leg ulcers | Advances in
Wound Care (liebertpub.com)
Link to the published article:
https://www.liebertpub.com/doi/10.1089/wound.2024.0040?url_ver=Z39.88-2003&rfr_i
d=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed